Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

Diabetes, Obesity & Metabolism
Yutaka SeinoKohei Kaku

Abstract

To evaluate the efficacy and safety of alogliptin added to metformin versus metformin monotherapy in Japanese patients with type 2 diabetes who achieved inadequate glycaemic control on metformin (500 or 750 mg/day) + diet/exercise. In a randomized, double-blind trial, 288 patients with type 2 diabetes mellitus T2DM received either 12.5 or 25 mg alogliptin once daily + metformin or placebo + metformin for 12 weeks. Thereafter, 276 patients continued on one of the two alogliptin dosages + metformin in an open-label extension for 40 weeks. The primary efficacy endpoint in the randomized, double-blind phase was the change in HbA1c from baseline (week 0) to the end of treatment (week 12). The primary endpoint during the long-term extension phase was adverse events. After 12 weeks both dosages of alogliptin + metformin produced significantly greater changes from baseline in HbA1c than placebo (metformin monotherapy: with changes in LS means - 0.55 and - 0.64% vs. 0.22%, respectively; p < 0.0001). Incidences of adverse effects were comparable between groups, with no increases in hypoglycaemia. Over 52 weeks, there were no safety or tolerability concerns with alogliptin when added to metformin. Alogliptin 12.5 and 25 mg once daily was ...Continue Reading

References

Jun 9, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·UNKNOWN IDF Clinical Guidelines Task Force
Dec 26, 2007·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Peter E H SchwarzJaakko Tuomilehto
May 8, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Veronika VlckovaSaad A W Shakir
Oct 6, 2009·Journal of the American Pharmacists Association : JAPhA·Joshua J Neumiller
Oct 28, 2009·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Helena W RodbardStanley S Schwartz
Apr 22, 2010·Journal of Diabetes Investigation·Yutaka SeinoDaisuke Yabe
Oct 19, 2010·Journal of Diabetes Investigation·Yutaka SeinoKohjiro Ueki
Feb 20, 2012·Journal of Diabetes Investigation·Bo Ahrén

❮ Previous
Next ❯

Citations

Sep 27, 2013·Drug Design, Development and Therapy·Annalisa CapuanoKatherine Esposito
Mar 8, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Masato OdawaraManabu Suzuki
Mar 26, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Paul CraddyK Ian Johnson
Mar 22, 2014·Expert Opinion on Pharmacotherapy·Yutaka Seino, Daisuke Yabe
Apr 22, 2014·Expert Opinion on Drug Metabolism & Toxicology·Theodosios D FilippatosMoses S Elisaf
Nov 27, 2015·Expert Opinion on Drug Safety·Daisuke Yabe, Yutaka Seino
Dec 25, 2015·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Abdulrahman S Alanazi
Sep 30, 2015·Diabetes/metabolism Research and Reviews·Wenjia YangLinong Ji
Dec 3, 2014·The Medical Clinics of North America·Joshua J Neumiller
Nov 29, 2013·The Annals of Pharmacotherapy·Courtney I JarvisDerek Charron
Jan 15, 2014·Hospital Pharmacy·Dennis J CadaDanial E Baker
Jul 25, 2019·Expert Opinion on Pharmacotherapy·Jingbo HuYufen Zhao
Dec 22, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yuli CaiLulu Chen
Oct 28, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kohei KakuTakashi Oohira
Jun 8, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ira GantzUNKNOWN Omarigliptin Study 015 Group
Jan 1, 2016·Expert Review of Endocrinology & Metabolism·Joshua J Neumiller, Daniel Q Holland
Nov 1, 2014·Expert Review of Endocrinology & Metabolism·Yutaka Seino, Daisuke Yabe
Feb 19, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yoshio NagaiYasushi Tanaka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.